Teva Pharmaceutical Industries (TEVA) Income from Non-Controlling Interests (2017 - 2025)

Teva Pharmaceutical Industries has disclosed Income from Non-Controlling Interests across 9 years of filings, most recently posting $1.0 million for Q3 2025.

• Quarterly Income from Non-Controlling Interests fell 97.87% year-over-year to $1.0 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $7.0 million (up 102.19% YoY) and the FY2025 annual result came in at $7.0 million, up 102.19% from the prior year.
• Income from Non-Controlling Interests declined to $1.0 million in Q3 2025, from $6.0 million in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at $47.0 million in Q3 2024 and troughed at -$280.0 million in Q1 2024.
• A 5-year average of -$21.3 million and a median of $3.0 million in 2022 frame the typical range for Income from Non-Controlling Interests.
• Biggest YoY gain for Income from Non-Controlling Interests was 487.5% in 2024; the steepest drop was 1550.0% in 2024.
• Tracing TEVA's Income from Non-Controlling Interests over 5 years: stood at $7.0 million in 2021, then slumped by 557.14% to -$32.0 million in 2022, then surged by 112.5% to $4.0 million in 2023, then plunged by 1550.0% to -$58.0 million in 2024, then surged by 101.72% to $1.0 million in 2025.
• Business Quant data shows TEVA's Income from Non-Controlling Interests at $1.0 million in Q3 2025, $6.0 million in Q1 2025, and -$58.0 million in Q4 2024.